Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:18:01.462Z.
Calculation as of: 2026-10-06T21:18:01.462Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cae73e0f7d7453288b6b30bb28ae33caa2dcc4a3490ac3f0933bc7bc3ce0e433
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | $1.84B | N/A | N/A | N/A | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | N/A | 0.91 | 8.33 | 8.33 |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | N/A | N/A | N/A | N/A |
| Immunome, Inc. (IMNM)vs › | $1.85B | N/A | N/A | N/A | N/A |
| Azenta, Inc. (AZTA)vs › | $1.81B | N/A | 2.28 | 2.28 | 2.28 |
| Novavax, Inc. (NVAX)vs › | $1.86B | N/A | N/A | N/A | N/A |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 1.43 | 2.03 | 10.26 | 11.33 |
| Xencor, Inc. (XNCR)vs › | $1.81B | N/A | 3.15 | 3.15 | 3.15 |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | N/A | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
